GLP-1 Medications: Benefits, Options & Genetic Insights

Last reviewed: May 21, 2026

Last updated: May 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists are a class of medications that activate glucagon-like peptide-1 receptors, regulating appetite and blood glucose levels. Clinical data shows GLP-1 medications have demonstrated weight loss and cardiovascular benefits in multiple randomized controlled trials, with semaglutide showing approximately 15% body weight reduction over 68 weeks in the STEP trials and tirzepatide demonstrating up to 22% reduction in the SURMOUNT trials.

Beyond standard medication options, understanding your genetic predispositions in peptide pathways may provide valuable context for provider conversations. PlexusDx uses licensed 503A compounding pharmacies to provide access to compounded GLP-1 medications alongside precision genetic testing, enabling a more personalized approach than one-size-fits-all prescribing.

The GLP-1 Medication Class: Mechanism and Clinical Purpose

GLP-1 receptor agonists mimic the glucagon-like peptide-1 hormone, which signals satiety to the brain and slows gastric emptying. This dual action addresses appetite regulation and metabolic control, distinguishing GLP-1s from older weight management or diabetes medications that relied on different physiological pathways.

Originally developed for type 2 diabetes management, GLP-1 medications have expanded into broader metabolic wellness due to demonstrated cardiovascular safety and weight loss efficacy. Major cardiovascular outcome trials, including LEADER (liraglutide) and PIONEER (semaglutide oral), showed reduced cardiovascular events in patients with diabetes or obesity-related conditions.

Comparing Injectable and Oral GLP-1 Options: Administration and Evidence

GLP-1 medications are available in two primary delivery formats: weekly subcutaneous injections and daily oral tablets. Each format has distinct pharmacokinetics, adherence profiles, and clinical evidence supporting their efficacy. Your provider may recommend one format over another based on your medical history, preference, and treatment goals.

Medication Type	Delivery Method	Dosing Schedule	Key Clinical Evidence
Semaglutide (compounded)	Subcutaneous injection or oral	Weekly injection or daily oral tablet	STEP trials: ~15% weight loss; cardiovascular benefit in SUSTAIN-6
Tirzepatide (compounded)	Subcutaneous injection or oral	Weekly injection or daily oral tablet	SURMOUNT trials: up to 22% weight loss; dual GLP-1/GIP receptor action
Liraglutide	Daily subcutaneous injection	Once daily	LEADER trial: cardiovascular safety; approximately 5-8% weight loss
Dulaglutide	Subcutaneous injection	Once weekly	REWIND trial: cardiovascular protection; moderate weight loss effect

GLP-1 Efficacy Variability: Why Genetic Predispositions May Matter

Clinical data shows considerable variability in individual GLP-1 response—some patients achieve 20%+ weight loss while others see more modest results. This variation stems partly from differences in GLP-1 receptor expression, metabolic capacity, and genetic predispositions in peptide signaling pathways. Understanding your genetic background may help contextualize expected outcomes.

Key genetic variants such as GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313 influence how your body's GLP-1 and GIP signaling systems function. While genetic predispositions do not predict exact medication response, they may provide providers with additional information to support treatment selection and goal-setting conversations.

Safety Considerations and Who Should Evaluate GLP-1 Treatment

GLP-1 medications are contraindicated in personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Nausea, vomiting, and gastrointestinal disturbances are common early side effects, typically dose-dependent and often transient. Serious but rare adverse events include pancreatitis and gallbladder complications; immediate medical attention is warranted if severe abdominal pain develops.

Appropriate candidates for GLP-1 therapy include adults with type 2 diabetes, obesity-related conditions, or cardiovascular risk factors, as determined by qualified healthcare providers. Compounded GLP-1 access through PlexusDx requires a valid prescription and medical consultation. Your provider should evaluate your full medical history, current medications, and treatment goals before initiating therapy.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context around your genetic predispositions in GLP-1 and GIP receptor pathways. The test screens variants including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—regions that influence metabolic regulation and appetite signaling. This information should be interpreted with a qualified healthcare provider as part of a comprehensive treatment discussion.

Understanding your peptide genetic predispositions does not predict your exact medication response or guarantee specific weight loss outcomes. Instead, genetic insights may help providers recognize patterns in your metabolic biology and tailor counseling around realistic expectations, dosing strategies, and potential side effect tolerance. The Precision Peptide Genetic Test ($99 add-on or $298 standalone) is available alongside all PlexusDx compounded GLP-1 and tirzepatide offerings.

When combined with a provider consultation, genetic predisposition data can support a more informed, precision-guided conversation about which compounded GLP-1 option—injectable semaglutide, oral semaglutide, compounded tirzepatide injection, or oral tirzepatide—aligns best with your individual biology and health objectives. PlexusDx's licensed 503A compounding pharmacies ensure quality and consistency for all compounded peptide medications.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral is $349/mo month-to-month, or from $279/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Which GLP-1 medications besides semaglutide and tirzepatide does the article list?

The article's comparison table adds liraglutide and dulaglutide. Liraglutide is described as a once-daily subcutaneous injection tied to the LEADER trial, with roughly 5 to 8 percent weight loss. Dulaglutide is listed as a once-weekly subcutaneous injection associated with the REWIND trial, described as showing cardiovascular protection and a moderate weight-loss effect.

How do injectable and oral options differ in how often they are taken?

The article splits the class into two delivery formats: weekly subcutaneous injections and daily oral tablets. It says each format has distinct pharmacokinetics, adherence profiles, and supporting clinical evidence, and that a provider may recommend one over the other based on medical history, personal preference, and treatment goals. The choice is presented as a clinical decision, not a shopping preference.

Which rare complications does the post say need immediate medical attention?

The article names pancreatitis and gallbladder complications as serious but rare adverse events, and says immediate medical attention is warranted if severe abdominal pain develops. It separately lists a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 as contraindications to the class, alongside common early side effects like nausea and vomiting.

What weight-loss figures does the article attribute to the STEP and SURMOUNT programs?

The article cites approximately 15 percent body weight reduction over 68 weeks for semaglutide in the STEP trials, and up to 22 percent for tirzepatide in the SURMOUNT trials. It presents both as trial-level averages across study populations. The same post stresses that individual results vary widely, with some people well above and others well below those figures.

What does the article say is required to access a compounded GLP-1 through PlexusDx?

It says compounded GLP-1 access through PlexusDx requires a valid prescription and a medical consultation, with a provider evaluating your full medical history, current medications, and treatment goals before therapy begins. The article also states that PlexusDx uses licensed 503A compounding pharmacies for these medications.

Related Reading

• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Glp 1 Medications
• How Do Genetic Variations Impact Glp 1 Response
• Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.